Center for Lymphoma and Myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research.

For decades, Weill Cornell has been a leader in the research revolution that's making lymphoma a survivable disease.